8-K: Moleculin's Annamycin Shows No Cardiotoxicity in 90 Subjects

Moleculin Biotech announced an independent assessment confirmed Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials in 90 subjects.

Summary

• Moleculin Biotech, Inc. received a new independent assessment confirming the absence of cardiotoxicity for its drug Annamycin in 90 subjects.
• This data spans five clinical trials for acute myeloid leukemia (AML) and soft tissue sarcoma (STS), where Annamycin was used as monotherapy and in combination with cytarabine.
• Most subjects (65 out of 90) were treated above the FDA's recommended lifetime maximum for other anthracyclines (550 mg/m2), with one subject receiving over 6500 mg/m2, without evidence of cardiotoxicity.
• The assessment included serial 12-lead ECGs, transthoracic echocardiography with centralized global longitudinal strain (GLS) analysis, and cardiac biomarker (troponins I and T) concentration measurements.
• Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and lack the cardiotoxicity common with currently prescribed anthracyclines.
• The company is advancing Annamycin in a pivotal, adaptive design Phase 3 trial (MIRACLE Trial, MB-108) for relapsed or refractory AML in combination with cytarabine (AnnAraC).
• A successful Phase 1B/2 study (MB-106) has substantially de-risked the development pathway towards potential FDA approval for Annamycin in AML.

Sentiment

Score: 8

Explanation: The confirmation of Annamycin's non-cardiotoxicity, even at high doses, is a major positive development that significantly de-risks the drug and highlights a potentially enormous market opportunity. This addresses a critical unmet need in oncology. The primary concern is the explicit mention of the need for significant additional financing without current commitments, which introduces a funding risk.

Positives

• Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials involving 90 subjects.
• 65 of the 90 subjects were treated above the FDA's lifetime maximum cumulative anthracycline exposure (550 mg/m2), with one subject exceeding 6500 mg/m2, without showing cardiotoxicity.
• Annamycin is designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity common with existing anthracyclines.
• The drug has shown promising early activity in treating multiple oncology indications, including AML and STS.
• The successful Phase 1B/2 study (MB-106) has substantially de-risked the development pathway towards potential FDA approval for Annamycin in AML.
• The market opportunity for Annamycin is potentially enormous, given its non-cardiotoxicity and observed efficacy in tumor animal models.

Negatives

• Moleculin will require significant additional financing to conduct its clinical trials.
• The Company currently has no commitments for the required additional financing.
• The achievement of milestones described in the press release is contingent on the Company's ability to secure timely financing.

Risks

• Moleculin will require significant additional financing, for which the Company has no commitments, to conduct its clinical trials.
• The milestones described in the press release assume the Company's ability to secure such financing on a timely basis.
• The Company relies on the reports of its expert with regard to the absence of cardiotoxicity.
• The referenced dataset is subject to the review of data from future subjects in current and future clinical trials.
• Long-term cardiac follow-up with active subjects in current trials is still needed.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. Risk Factors in the most recently filed Form 10-K and subsequent Form 10-Q filings.

Future Outlook

The company is looking forward to adding to the current dataset and completing long-term cardiac follow-up with active subjects in its current trials. They remain focused on advancing Annamycin development programs to address unmet medical needs in difficult-to-treat cancers. The MIRACLE clinical trial is expected to continue recruitment, treatment, and receipt of unblinded data for its first 45 subjects.

Management Comments

• "As we closely approach almost 100 subjects that have received Annamycin (also known by the name naxtarubicin) which have been reviewed by our expert, we continue to be encouraged by the potential of Annamycin. This additional independent report of additional datasets provides further validation of the absence of cardiotoxicity." Walter Klemp, Chairman and CEO.
• "Annamycin continues to demonstrate an absence of cardiotoxicity, even in subjects who have received far more than the lifetime maximum cumulative anthracycline exposure established by the US Food and Drug Administration (FDA)." Walter Klemp, Chairman and CEO.
• "In fact, 65 of the 90 subjects evaluated have been taken over the FDAs lifetime maximum of 550 mg/m2 and with one of them being taken over 6500 mg/m2." Walter Klemp, Chairman and CEO.
• "Our growing body of positive data for Annamycin continues to bolster our confidence in our belief that Annamycin is truly a next generation anthracycline, especially in light of the growing efficacy data that we have previously reported in the treatment of AML and STS." Walter Klemp, Chairman and CEO.
• "We remain focused on advancing our Annamycin development programs and ultimately, addressing the medical unmet needs of people with difficult to treat cancers." Walter Klemp, Chairman and CEO.
• "We believe Annamycin has the potential to become the first ever non-cardiotoxic anthracycline." Walter Klemp, Chairman and CEO.
• "Coupled with its observed ability in a wide range of tumor animal models to avoid cross-resistance with existing anthracyclines and to demonstrate equal or greater efficacy, we believe the market opportunity for Annamycin is potentially enormous." Walter Klemp, Chairman and CEO.

Industry Context

The announcement positions Annamycin as a potentially groundbreaking treatment in oncology, particularly for cancers currently treated with cardiotoxic anthracyclines. These existing treatments, while effective against cancer, cause significant and often permanent heart damage, leading to cardiomyopathy, heart failure, and even cardiac-related deaths that can surpass cancer recurrence deaths decades after diagnosis. Annamycin's confirmed lack of cardiotoxicity, coupled with its ability to avoid multidrug resistance and demonstrate efficacy, addresses a critical unmet medical need in a market where nearly half of all cancers and 60% of childhood cancers are treated with cardiotoxic drugs.

Comparison to Industry Standards

• Current anthracyclines, commonly used in nearly half of all cancers and 60% of childhood cancers, are known to be cardiotoxic, causing progressive and persistent heart damage.
• This cardiotoxicity can lead to cardiomyopathy, clinical heart failure, the need for a heart transplant, or death, with cardiac-related deaths exceeding cancer recurrence deaths 30 years after diagnosis.
• Annamycin, in contrast, has consistently demonstrated no evidence of cardiotoxicity across five clinical trials in 90 subjects, even when administered at doses far exceeding the FDA's lifetime maximum cumulative exposure (550 mg/m2) for other anthracyclines.
• Annamycin is designed to avoid multidrug resistance mechanisms, a common challenge with existing anthracyclines, and has shown equal or greater efficacy in a wide range of tumor animal models.
• The company believes Annamycin has the potential to become the first non-cardiotoxic anthracycline, offering a significant advantage over standard treatments like doxorubicin or daunorubicin which carry substantial cardiac risks.

Stakeholder Impact

• Shareholders: Positive impact due to significant de-risking of a key pipeline asset (Annamycin), potentially increasing its market value and future revenue prospects. However, the need for future financing without commitments introduces dilution risk.
• Patients (AML, STS): Highly positive impact as Annamycin offers a potentially safer and equally or more efficacious treatment option, avoiding the severe cardiotoxicity associated with current anthracyclines.
• Healthcare Providers: Provides a new, potentially superior treatment option for difficult-to-treat cancers, improving patient outcomes and reducing long-term cardiac complications.
• Regulatory Authorities (FDA): The strong safety profile, particularly the absence of cardiotoxicity at high doses, could facilitate a smoother regulatory pathway for approval.

Next Steps

• Add to the current dataset for Annamycin.
• Complete long-term cardiac follow-up with active subjects in current trials.
• Continue recruitment and treatment for the MIRACLE clinical trial (MB-108).
• Receive unblinded data for the first 45 subjects of the MIRACLE clinical trial.
• Advance Annamycin development programs to address unmet medical needs.
• Potential future filings with additional feedback from the FDA and foreign equivalents regarding the AML development pathway.

Key Dates

Recommendation

The confirmation of Annamycin's non-cardiotoxicity in a substantial number of subjects, even at doses far exceeding FDA limits for other anthracyclines, is a highly significant de-risking event for Moleculin's lead asset. This addresses a major limitation of current standard-of-care anthracyclines and opens up a potentially enormous market opportunity. While the need for future financing is a concern, the clinical data presented here provides a strong foundation for future value creation and potential partnerships or successful capital raises. The long-term implications for patient outcomes and market share are very positive, making this a compelling investment opportunity despite the financing risk.

Keywords

Annamycin, cardiotoxicity, anthracycline, acute myeloid leukemia, AML, soft tissue sarcoma, STS, oncology, cancer treatment, Moleculin Biotech, MBRX, clinical trials, drug development, FDA, naxtarubicin